PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
PR Newswire•13/11/2026•08:00 ET
0
Key Highlights
- ➤EsoGuard began receiving Medicare payments in October at its established fee-schedule rate
- ➤Lucid performed 2,871 EsoGuard tests and recognized $1.2 million revenue in 3Q26
- ➤Veris achieved implantable monitor design freeze and began 90-day GLP animal study
- ➤PAVmed operating expenses reached approximately $6.8 million, including $1.0 million stock compensation
- ➤PAVmed reported non-GAAP adjusted loss of $1.2 million, or $(0.19) per share
Expert Statements
Lishan Aklog, Chairman and Chief Executive Officer of PAVmed
“We're very encouraged by developments across the PAVmed portfolio”
Lishan Aklog, Chairman and Chief Executive Officer of PAVmed
“Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone.”
Lishan Aklog, Chairman and Chief Executive Officer of PAVmed
“As Lucid's largest common shareholder, PAVmed stands to benefit directly from Lucid's substantial near-term revenue opportunity.”
Lishan Aklog, Chairman and Chief Executive Officer of PAVmed
“Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission.”
Lishan Aklog, Chairman and Chief Executive Officer of PAVmed
“We are also now actively engaged with FDA on both PortIO and Octeris.”
Lishan Aklog, Chairman and Chief Executive Officer of PAVmed
“We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results PR Newswire
Lucid Diagnostics' EsoGuard(®) now fully reimbursed by Medicare nationwide
Get started
Create a free account to read the full story.